Active Filter(s):
Details:
Pursuant to the Agreement, Essex and Henlius will co-develop the bevacizumab HLX04 for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD).
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: HLX04
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Henlius
Deal Size: $25.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement October 15, 2020